Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $7.5400 (5.6%) ($6.7700 - $7.9600) on Thu. Mar. 19, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.88% (three month average) | RSI | 33 | Latest Price | $7.5400(5.6%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -1.5% a day on average for past five trading days. | Weekly Trend | TGTX declines -24% a week on average for past two weeks. | Market Behavior | Normal for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(66%) ARKG(60%) ARKK(58%) IBB(58%) IWO(57%) | Factors Impacting TGTX price | TGTX will decline at least -2.94% in a week (0% probabilities). VIXM(-40%) VXX(-38%) UUP(-8%) TLT(-5%) IGOV(2%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.94% (StdDev 5.88%) | Hourly BBV | 0 () | Intraday Trend | 7% | | | |
|
1 - 5 Day Possible Target | $-30.24(-501.06%) | Resistance Level | $11.23 | 5 Day Moving Average | $7.69(-1.95%) | 10 Day Moving Average | $8.92(-15.47%) | 20 Day Moving Average | $11.23(-32.86%) | To recent high | -52.8% | To recent low | 5.6% | Market Cap | $955m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |